Peter Rossing
Steno Diabetes Center Copenhagen · Steno Diabetes Cneter Copenhagen · Head of department
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter Rossing as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:17 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06954090 · Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudySteno Diabetes Center Copenhagen · enrolling by invitation · Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria · principal investigator
- Ph2NCT06906081 · Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN StudyPeter Rossing · recruiting · Cardiovascular Autonomic Neuropathy, Type 2 Diabetes, Diabetic Neuropathies · principal investigator
- Ph2NCT06600412 · The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.River 3 Renal Corp. · recruiting · Diabetic Kidney Disease · principal investigator
- Ph3NCT06082063 · Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesSteno Diabetes Center Copenhagen · recruiting · Cardiovascular Diseases, Heart Failure, Type 1 Diabetes · principal investigator
- N/ANCT04635670 · Effects of Probiotics and Fibers on Albuminuria in Persons With Type 1 DiabetesSteno Diabetes Center Copenhagen · completed · Type 1 Diabetes, Nephropathy, Albuminuria · principal investigator
- N/ANCT04154020 · Treatment of Ulcers Associated With Hammer, Mallet and Claw Toe Deformities in the Diabetic Patient SettingSteno Diabetes Center Copenhagen · completed · Diabetic Foot Ulcer, Hammer Toe, Mallet Toe · study director
- N/ANCT04073927 · Effect of Butyrate on Inflammation and Albuminuria in Patients With Albuminuria, Type 1 Diabetes and Intestinal InflammationSteno Diabetes Center Copenhagen · unknown · Diabetes Mellitus, Type 1, Albuminuria · principal investigator
- N/ANCT03721991 · GABA Treatment in Subjects With Type 1 DiabetesSteno Diabetes Center Copenhagen · unknown · Type 1 Diabetes Mellitus · study chair
- N/ANCT03509454 · PeRsOnalising Treatment Of Diabetic Nephropathy:Peter Rossing · completed · Diabetes Mellitus, Type 1, Diabetes Complications, Diabetic Nephropathies · study chair
- Ph1NCT03509870 · Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot WoundsSteno Diabetes Center Copenhagen · terminated · Diabetic Foot Ulcer · principal investigator
- N/ANCT02749942 · RISCAID Study: Remote ISchemic Conditioning for Angiopathy In DiabetesSteno Diabetes Center Copenhagen · completed · Peripheral Arterial Disease · principal investigator
- Ph4NCT02545738 · Antiproteinuric Effects of Liraglutide TreatmentSteno Diabetes Center Copenhagen · completed · Diabetic Kidney Disease · principal investigator
- N/ANCT02494557 · Risk Stratification for Coronary Artery Disease With Type 2 Diabetic PatientsAcarix · completed · Coronary Arteriosclerosis · principal investigator
- N/ANCT02138565 · Effect of Bariatric Surgery on Kidney FunctionSteno Diabetes Center Copenhagen · completed · Obese Subjects Who Will Undergo Gastric By-pass Surgery · principal investigator
- Ph2/Ph3NCT02040441 · Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With NormoalbuminuriaPeter Rossing · completed · Diabetic Nephropathy, Diabetic Retinopathy · study chair
- Ph4NCT01499108 · Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 DiabetesPeter Rossing · completed · Type 2 Diabetes · principal investigator
- N/ANCT01171248 · Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 DiabetesSteno Diabetes Center Copenhagen · completed · Type 1 Diabetes, Hypertension · principal investigator
- Ph4NCT00311870 · Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic NephropathySteno Diabetes Center Copenhagen · completed · Diabetic Nephropathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:17 UTC. The ranking covers the 200 most relevant of 238 PubMed records, and a shared surname and initials can bring in a namesake. All 238 on PubMed
- Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med · 20204,442 citationsRCR 255.6
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.N Engl J Med · 20202,334 citationsRCR 128.9
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.N Engl J Med · 20241,618 citationsRCR 281.5
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.N Engl J Med · 20211,438 citationsRCR 97.0
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur Heart J · 20221,027 citationsRCR 89.0
- 586 citationsRCR 20.9
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.Lancet Diabetes Endocrinol · 2021433 citationsRCR 28.3
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.Kidney Int · 2021360 citationsRCR 24.4
- 301 citationsRCR 17.3
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.N Engl J Med · 2025276 citationsRCR 81.0